CoChat

Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations

Open access
Ludolph, Andrea G, Udvardi, Patrick T, Schaz, Ulrike, Henes, Carolin, Adolph, Oliver, Weigt, Henry U, Fegert, Joerg M, Boeckers, Tobias M, Föhr, Karl J · 2010 · British Journal of Pharmacology
Cited by 82

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background and purpose: There is increasing evidence that not only the monoaminergic but also the glutamatergic system is involved in the pathophysiology of attention‐deficit hyperactivity disorder (ADHD). Hyperactivity of glutamate metabolism might be causally related to a hypoactive state in the dopaminergic system. Atomoxetine, a selective noradrenaline reuptake inhibitor, is the first non‐stimulant approved for the treatment of this disorder. Here we have evaluated the effects of atomoxetine on glutamate receptors in vitro. Experimental approach: The whole‐cell configuration of the patch‐clamp technique was used to analyse the effect of atomoxetine on N‐methyl‐d‐aspartate (NMDA) receptors in cultured rodent cortical and hippocampal neurons as well as on NMDA receptors heterologously expressed in human TsA cells. Key results: Atomoxetine blocked NMDA‐induced membrane currents. Half‐maximal inhibition emerged at about 3 µM which is in the range of clinically relevant concentrations found in plasma of patients treated with this drug. The inhibition was voltage‐dependent, indicating an open‐channel blocking mechanism. Furthermore, the inhibitory potency of atomoxetine did not vary when measured on NMDA receptors from different brain regions or with different subunit compositions. Conclusions and implications: The effective NMDA receptor antagonism by atomoxetine at low micromolar concentrations may be relevant to its clinical effects in the treatment of ADHD. Our data provide further evidence that altered glutamatergic transmission might play a role in ADHD pathophysiology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2010.00707.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 82

Metadata

Authors
Ludolph, A. G., Udvardi, P. T., Schaz, U., Henes, C., Adolph, O., Weigt, H. U., Fegert, J. M., Boeckers, T. M., & Föhr, K. J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2010-04-26
Volume
160
Issue
2
Pages
283-291
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1530918435
Cited by
82
References
9
FWCI
2.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00707.x
The paper
Ludolph, A. G., Udvardi, P. T., Schaz, U., Henes, C., Adolph, O., Weigt, H. U., Fegert, J. M., Boeckers, T. M., & Föhr, K. J. (2010). Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00707.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.